Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-08-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to determine whether the investigational drug cetuximab, (Erbitux) alone or with paclitaxel (Taxol) can stabilize the growth of urothelial cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer

NCT03575013

Urothelial Carcinoma

COMPLETED PHASE1

Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)

NCT02853305

Urothelial Carcinoma Associated 1 RNA, Human

COMPLETED PHASE3

First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma

NCT03324282

Bladder Carcinoma

TERMINATED PHASE2

A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy

NCT05366725

Urothelial Cancer

COMPLETED

Intravesicular Abraxane for Treatment-Refractory Bladder Cancer

NCT00583349

Bladder Cancer

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This research study is being done to find out if cetuximab, alone or with paclitaxel will slow the growth of urothelial cancers. Cetuximab is an antibody that blocks a protein called epidermal growth factor receptor (EGFR). EGFR sits on the outside of tumor cells and controls tumor cell growth. This agent has been looked at alone and with other chemotherapy drugs including paclitaxel. It has been found to be safe and can shrink other types of cancer.

This research study is also being done to find out if cetuximab, alone or with paclitaxel shrinks urothelial tumors. If it extends the time the tumors shrink. If it helps people live longer.

The purpose of this research study is to find out what effects (good and bad) these treatments have on you and your cancer. We do not know if you will benefit from this research study. It is possible that your condition will get better, but it is also possible that there will be no effect on your condition or that your condition will get worse. We can use what we learn from this research study to help other people with the same disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urologic Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cetuximab alone

Cetuximab 250mg/m2 IV weekly during each 28 day cycle. Arm A closed to accrual June 11, 2009 for lack of efficacy

Group Type OTHER

Cetuximab

Intervention Type DRUG

Cetuximab 250mg/m2 IV weekly for each 28 day cycle.

Cetuximab with Paclitaxel

Paclitaxel 80 mg/m2 IV weekly for every 28 day cycle. Cetuximab 250mg/m2 IV weekly for every 28 day cycle.

Group Type OTHER

Cetuximab

Intervention Type DRUG

Cetuximab 250mg/m2 IV weekly for each 28 day cycle.

Paclitaxel

Intervention Type DRUG

Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cetuximab

Cetuximab 250mg/m2 IV weekly for each 28 day cycle.

Intervention Type DRUG

Paclitaxel

Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Taxol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed carcinoma of the urothelium (bladder,renal pelvis, ureter)
* Measurable disease by RECIST
* Patients who received only one prior systemic non-taxane regimen for urothelial cancer. May have received this in the adjuvant or neoadjuvant setting or for advanced disease.
* Signed IRB approved consent
* Must have tissue available for EGFR assessment and additional correlative studies
* ECOG PS 0-2
* 18 years of age or older
* Not of child bearing potential or negative pregnancy test within 7 days of treatment
* ANC greater than or equal to 1,500/ul
* Platelets greater than or equal to 100,00/ul
* Creatinine less than or equal to 2x institutional ULN or create. clearance greater than or equal to 30, bilirubin less than or equal to 1.5x ULN, AST\&ALT less than or equal to 5x ULN

Exclusion Criteria

* Received more than one prior regimen for advanced disease
* Prior radiation to more than 30% of marrow containing skeleton
* Prior therapy that specifically and directly targets the EGFR pathway
* Prior severe infusion reaction to a monoclonal antibody, pre-existing neuropathy greater than or equal to grade 2
* Prior reaction to Cremophor EL
* Known acute hepatitis B or C or known HIV
* Active or uncontrolled infection
* Significant history of uncontrolled cardiac disease
* Any concurrent chemotherapy not indicated in this study; or
* Any other investigational agents

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No